{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:43:39Z","timestamp":1794933819355,"version":"4.9.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005809","name":"Hyderabad Eye Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-024-03657-6","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T09:03:38Z","timestamp":1725354218000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment of ocular surface squamous neoplasia in an Indian rural facility: a study of 38 eyes"],"prefix":"10.1186","volume":"24","author":[{"given":"Ayushi","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Ghose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Rathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swathi","family":"Kaliki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"3657_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4103\/meajo.MEAJO_275_19","volume":"27","author":"S Kaliki","year":"2020","unstructured":"Kaliki S, Das AV. Ocular and Periocular Tumors in India: an EyeSmart Electronic Medical Record Analysis of 9633 cases from a Referral Center. Middle East Afr J Ophthalmol. 2020;27:199\u2013203.","journal-title":"Middle East Afr J Ophthalmol"},{"key":"3657_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1097\/00003226-200310000-00015","volume":"22","author":"S Basti","year":"2003","unstructured":"Basti S, Macsai MS. Ocular surface squamous neoplasia: a review. Cornea. 2003;22:687\u2013704.","journal-title":"Cornea"},{"key":"3657_CR3","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S0161-6420(94)31328-5","volume":"101","author":"GA Lee","year":"1994","unstructured":"Lee GA, Williams G, Hirst LW, Green AC. Risk factors in the development of ocular surface epithelial dysplasia. Ophthalmology. 1994;101:360\u20134.","journal-title":"Ophthalmology"},{"key":"3657_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.4103\/ijo.IJO_1665_20","volume":"69","author":"CL Shields","year":"2021","unstructured":"Shields CL, Constantinescu AB, Paulose SA, Yaghy A, Dalvin LA, Shields JA, et al. Primary treatment of ocular surface squamous neoplasia with topical interferon alpha-2b: comparative analysis of outcomes based on original tumor configuration. Indian J Ophthalmol. 2021;69:563\u20137.","journal-title":"Indian J Ophthalmol"},{"key":"3657_CR5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jtos.2015.02.001","volume":"13","author":"AA Nanji","year":"2015","unstructured":"Nanji AA, Sayyad FE, Galor A, Dubovy S, Karp CL. High-resolution optical coherence tomography as an adjunctive tool in the diagnosis of corneal and conjunctival pathology. Ocul Surf. 2015;13:226\u201335.","journal-title":"Ocul Surf"},{"key":"3657_CR6","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1038\/s41433-023-02565-1","volume":"37","author":"R H\u04e7llhumer","year":"2023","unstructured":"H\u04e7llhumer R, Michelow P, Williams S. Demographics, clinical presentation and risk factors of ocular surface squamous neoplasia at a tertiary hospital, South Africa. Eye (Lond). 2023;37:3602\u20138.","journal-title":"Eye (Lond)"},{"key":"3657_CR7","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.3109\/02713683.2014.993086","volume":"40","author":"F Segev","year":"2015","unstructured":"Segev F, Mimouni M, Tessler G, Hilely A, Ofir S, Kidron D, et al. A 10-year survey: prevalence of ocular surface squamous neoplasia in clinically benign pterygium specimens. Curr Eye Res. 2015;40:1284\u20137.","journal-title":"Curr Eye Res"},{"key":"3657_CR8","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.ophtha.2012.02.049","volume":"119","author":"AA Kao","year":"2012","unstructured":"Kao AA, Galor A, Karp CL, Abdelaziz A, Feuer WJ, Dubovy SR. Clinicopathologic correlation of ocular surface squamous neoplasms at Bascom Palmer Eye Institute: 2001 to 2010. Ophthalmology. 2012;119:1773\u20136.","journal-title":"Ophthalmology"},{"key":"3657_CR9","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1001\/jamaophthalmol.2015.3335","volume":"133","author":"S Gichuhi","year":"2015","unstructured":"Gichuhi S, Macharia E, Kabiru J, Zindamoyen AM, Rono H, Ollando E, et al. Clinical presentation of ocular surface squamous neoplasia in Kenya. JAMA Ophthalmol. 2015;133:1305\u201313.","journal-title":"JAMA Ophthalmol"},{"key":"3657_CR10","doi-asserted-by":"publisher","first-page":"396","DOI":"10.4103\/0301-4738.100533","volume":"60","author":"GN Rao","year":"2012","unstructured":"Rao GN, Khanna RC, Athota SM, Rajshekar V, Rani PK. Integrated model of primary and secondary eye care for underserved rural areas: the L V Prasad Eye Institute experience. Indian J Ophthalmol. 2012;60:396\u2013400.","journal-title":"Indian J Ophthalmol"},{"key":"3657_CR11","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1001\/archopht.117.10.1393","volume":"117","author":"AE Fletcher","year":"1999","unstructured":"Fletcher AE, Donoghue M, Devavaram J, Thulasiraj RD, Scott S, Abdalla M, et al. Low uptake of eye services in rural India: a challenge for programs of blindness prevention. Arch Ophthalmol. 1999;117:1393\u20139.","journal-title":"Arch Ophthalmol"},{"key":"3657_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ophtha.2011.08.005","volume":"119","author":"YA Yousef","year":"2012","unstructured":"Yousef YA, Finger PT. Squamous carcinoma and dysplasia of the conjunctiva and cornea: an analysis of 101 cases. Ophthalmology. 2012;119:233\u201340.","journal-title":"Ophthalmology"},{"key":"3657_CR13","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/s41433-021-01422-3","volume":"35","author":"R H\u04e7llhumer","year":"2021","unstructured":"H\u04e7llhumer R, Williams S, Michelow P. Ocular surface squamous neoplasia: management and outcomes. Eye (Lond). 2021;35:1562\u201373.","journal-title":"Eye (Lond)"},{"key":"3657_CR14","doi-asserted-by":"publisher","first-page":"702","DOI":"10.4103\/0301-4738.195010","volume":"64","author":"S Kaliki","year":"2016","unstructured":"Kaliki S, Singh S, Iram S, Tripuraneni D. Recombinant interferon alpha 2b for ocular surface squamous neoplasia: an efficient and cost-effective treatment modality in Asian Indian patients. Indian J Ophthalmol. 2016;64:702\u20139.","journal-title":"Indian J Ophthalmol"},{"key":"3657_CR15","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/ICU.0b013e3283622a13","volume":"24","author":"AA Nanji","year":"2013","unstructured":"Nanji AA, Sayyad FE, Karp CL. Topical chemotherapy for ocular surface squamous neoplasia. Curr Opin Ophthalmol. 2013;24:336\u201342.","journal-title":"Curr Opin Ophthalmol"},{"key":"3657_CR16","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.ophtha.2016.02.034","volume":"123","author":"MG Joag","year":"2016","unstructured":"Joag MG, Sise A, Murillo JC, Sayed-Ahmed IO, Wong JR, Mercado C, et al. Topical 5-Fluorouracil 1% as primary treatment for ocular surface squamous neoplasia. Ophthalmology. 2016;123:1442\u20138.","journal-title":"Ophthalmology"},{"key":"3657_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/BF00166683","volume":"64","author":"RJ de Keizer","year":"1986","unstructured":"de Keizer RJ, de Wolff-Rouendaal D, van Delft JL. Topical application of 5-fluorouracil in premalignant lesions of cornea, conjunctiva and eyelid. Doc Ophthalmol. 1986;64:31\u201342.","journal-title":"Doc Ophthalmol"},{"key":"3657_CR18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ajo.2018.11.007","volume":"199","author":"N Venkateswaran","year":"2019","unstructured":"Venkateswaran N, Mercado C, Galor A, Karp CL. Comparison of topical 5-fluorouracil and interferon alfa-2b as primary treatment modalities for ocular surface squamous neoplasia. Am J Ophthalmol. 2019;199:216\u201322.","journal-title":"Am J Ophthalmol"},{"key":"3657_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jtos.2022.12.002","volume":"27","author":"A Wylegala","year":"2023","unstructured":"Wylegala A, Sripawadkul W, Zein M, Alvarez OP, Al Bayyat G, Galor A, et al. Topical 1% 5-fluorouracil eye drops as primary treatment for ocular surface squamous neoplasia: long-term follow-up study. Ocul Surf. 2023;27:67\u201374.","journal-title":"Ocul Surf"},{"key":"3657_CR20","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00417-011-1679-8","volume":"249","author":"N Gupta","year":"2011","unstructured":"Gupta N, Sachdev R, Tandon R. Ocular surface squamous neoplasia in xeroderma pigmentosum: clinical spectrum and outcome. Graefes Arch Clin Exp Ophthalmol. 2011;249:1217\u201321.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3657_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ajo.2018.10.011","volume":"198","author":"S Kaliki","year":"2019","unstructured":"Kaliki S, Jajapuram SD, Maniar A, Mishra DK. Ocular and Periocular Tumors in Xeroderma Pigmentosum: a study of 120 Asian Indian patients. Am J Ophthalmol. 2019;198:146\u201353.","journal-title":"Am J Ophthalmol"},{"key":"3657_CR22","doi-asserted-by":"publisher","first-page":"101265","DOI":"10.1016\/j.ajoc.2022.101265","volume":"25","author":"WV Lin","year":"2022","unstructured":"Lin WV, Rand GM, Miller ML, Marr BP, Suh LH. A case of sight threatening complications from topical 1% 5-fluorouracil in the treatment of ocular surface squamous neoplasia. Am J Ophthalmol Case Rep. 2022;25:101265.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"3","key":"3657_CR23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/bjo.2010.183244","volume":"95","author":"R Parrozzani","year":"2011","unstructured":"Parrozzani R, Lazzarini D, Alemany-Rubio E, Urban F, Midena E. Topical 1% 5-fluorouracil in ocular surface squamous neoplasia: a long-term safety study. Br J Ophthalmol. 2011;95(3):355\u20139.","journal-title":"Br J Ophthalmol"},{"key":"3657_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jtos.2022.12.009","volume":"28","author":"W Sripawadkul","year":"2023","unstructured":"Sripawadkul W, Reyes-Capo D, Zein M, Wylegala A, Albayyat G, Galor A, et al. Long term study of topical interferon \u03b1-2b eye drops as primary treatment of ocular surface squamous neoplasia. Ocul Surf. 2023;28:108\u201314.","journal-title":"Ocul Surf"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-024-03657-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-024-03657-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-024-03657-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T21:04:08Z","timestamp":1725397448000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-024-03657-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3657"],"URL":"https:\/\/doi.org\/10.1186\/s12886-024-03657-6","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"assertion":[{"value":"19 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of LV Prasad Eye Institute (March 24, 2023\/No LEC-BHR-R-03-23-1024). Informed consent was obtained from all individual participants\/parents\/legal guardian included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No conflicting relationship exists for any author","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"389"}}